SWG 5: The primary purpose of the Curative Therapies SWG is to accelerate work toward a cure for HIV, by linking local investigators of curative therapies for HIV to the UW/FHCRC CFAR. SWG 5 will leverage a large NIH investment in the Seattle-led consortium defeat HIV, one of three Martin Delaney collaboratories focused on the cure of HIV. We intend to facilitate use of CFAR resources, including the clinical, basic science, and developmental cores, to leverage efficiencies of scale, develop novel research questions, and collectively pursue additional NIH and foundation-sponsored resources for the study of curative therapies for HIV. A secondary purpose is to link Seattle investigators with outside leaders in the field, to develop local expertise as well as enhance areas of local strength. These activities will add value to the UW/FHCRC CFAR, US CFARs generally, and defeat HIV, by establishing an international center of excellence in the study of curative therapies for HIV. SWG 6: The Substance Abuse (SA) SWG will consist of over 30 UW investigators working in four research emphasis areas: Sexual Behavior-Substance Abuse Nexus, Substance Abusing HIV Positive Individuals, Prevention of HIV among Substance Abusing Individuals, HIV/STI Epidemiology among Substance Abusers.
The aims of the SWG 6 are: 1) develop synergy and collaboration among local HIV substance abuse researchers, and 2) seek funding for identified collaborative opportunities and encourage early career and minority investigators to pursue substance abuse and HIV/STI related research. The success of the SA SWG will be determined by publication of manuscripts or acceptance of abstracts, and/or submissions for grant funding by SA SWG members and other CFAR investigators. SWG 7: Coverage gaps with efficacious interventions underscore the importance of improving knowledge translation and implementation to achieve scale.
The aim of the Implementation Science SWG is to improve the speed, efficiency and quality of translation of scientific evidence on HIV/STI prevention and care into effective, large scale health programs. SWG 7 will leverage local and international multidisciplinary expertise to develop innovative models for implementing and scaling-up efficacious HIV/STI interventions, and apply rigorous methods to develop a base of evidence to guide scale-up. Specific activities include bimonthly IS meetings to develop novel research methods for IS, foster interdisciplinary collaboration, and coordinate responses to funding opportunities;annual IS symposia;fostering collaboration among CFAR cores and extra-CFAR institutions;and IS education, training and mentoring internationally and at the UW.

Public Health Relevance

Our 3 proposed SWGs propose to promote collaborations and accelerate the pace of research in three areas: Curative Therapies for HIV, bringing together scientists with many different areas of expertise to help them work toward a cure for HIV;Substance Abuse and HIV/STI, addressing the challenges presented by the intersection of substance abuse and HIV infection;and Implementation Science, providing critical resources to improve the quality of research and maximize the impact of HIV interventions worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-27
Application #
8683044
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
27
Fiscal Year
2014
Total Cost
$128,731
Indirect Cost
$32,015
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Dross, Sandra E; Munson, Paul V; Kim, Se Eun et al. (2016) Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. J Immunol :
Dombrowski, Julia C; Carey, James W; Pitts, Nicole et al. (2016) HIV provider and patient perspectives on the Development of a Health Department ""Data to Care"" Program: a qualitative study. BMC Public Health 16:491
Wang, Kerong; Chen, Wei-Ti; Zhang, Lin et al. (2016) Facilitators of and barriers to HIV self-management: Perspectives of HIV-positive women in China. Appl Nurs Res 32:91-97
Hien, Ha Thuc Ai; Thanh, Tran Tan; Thu, Nguyen Thi Mai et al. (2016) Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma. Mycoses :
Yang, Cui; Crane, Heidi M; Cropsey, Karen et al. (2016) Implementation of Computer-delivered Brief Alcohol Intervention in HIV Clinical Settings: Who Agrees to Participate? J Addict Res Ther 7:
Kohler, Pamela K; Tippett Barr, Beth A; Kangʼombe, Anderson et al. (2016) Safety, Feasibility, and Acceptability of the PrePex Device for Adult Male Circumcision in Malawi. J Acquir Immune Defic Syndr 72 Suppl 1:S49-55
Kerani, Roxanne P; Herbeck, Joshua T; Buskin, Susan E et al. (2016) Evidence of Local HIV Transmission in the African Community of King County, Washington. J Immigr Minor Health :
Wilson, Kate S; Wanje, George; Yuhas, Krista et al. (2016) A Prospective Study of Intimate Partner Violence as a Risk Factor for Detectable Plasma Viral Load in HIV-Positive Women Engaged in Transactional Sex in Mombasa, Kenya. AIDS Behav 20:2065-77
Levine, Molly; Beck, Ingrid; Styrchak, Sheila et al. (2016) Comparison of Matrix-Based and Filter Paper-Based Systems for Transport of Plasma for HIV-1 RNA Quantification and Amplicon Preparation for Genotyping. J Clin Microbiol 54:1899-901
Blanquart, François; Grabowski, Mary Kate; Herbeck, Joshua et al. (2016) A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. Elife 5:

Showing the most recent 10 out of 970 publications